Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

v3.20.1
Stockholders' Equity - Additional Information (Details) - USD ($)
3 Months Ended
Jan. 01, 2020
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Nov. 30, 2017
Jun. 30, 2017
Mar. 17, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common Stock, Shares Authorized   60,000,000   60,000,000      
Common Stock, Par or Stated Value Per Share   $ 0.0001   $ 0.0001      
Common Stock, Shares, Issued   48,038,506   47,004,764      
Common Stock, Shares, Outstanding   48,038,506   47,004,764      
Shelf Registration Statement, Maximum Authorized Securities         $ 100,000,000    
Equity Method Investment, Annual Equity Fee, Percentage             2.50%
Stock Issued During Period Value Common Shares For At The Market Offering     $ 355,000        
Stock Issued During Period, Value, Common Shares For Services     9,000        
Shelf Registration Statement, Remaining Authorized Securities   $ 41,400,000          
Amount received for issuance of common stock upon exercise of warrants   13,000 $ 0        
Non-vested Restricted Stock [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options   $ 4,400,000          
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition   1 year 4 months 24 days          
Performance Shares [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number   333,334          
2015 Incentive Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized           5,000,000  
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period   10 years          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant   494,805          
Common Shares [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Equity Method Investment, Annual Equity Fee, Percentage   2.50%          
Stock Issued During Period Shares Common Shares For At The Market Offering     90,269        
Stock Issued During Period Value Common Shares For At The Market Offering     $ 0        
Stock Issued During Period, Value, Common Shares For Services     $ 0        
Issuance of stock upon exercise of warrants   102,742 39,651        
Amount received for issuance of common stock upon exercise of warrants   $ 0 $ 0        
Fortress Biotech, Inc [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock Issued During Period, Shares, New Issues 1,459,305            
Agent [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Commission rate   3.00%          
Common Class A [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common Stock, Shares Authorized   7,000,000          
Common Stock, Shares, Issued   7,000,000